Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
Portfolio Pulse from Nina Zdinjak
InterCure Ltd. (NASDAQ:INCR) reported a decline in revenue for the first half of 2024 due to damages from a terror attack but maintained profitability. The company is expanding its partnership with Cookies in Germany and expects double-digit growth in the second half of 2024. InterCure's shares rose by 2.47% following the announcement.
August 30, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InterCure Ltd. reported a decline in revenue for H1 2024 due to damages from a terror attack but maintained profitability. The company is expanding its partnership with Cookies in Germany and expects double-digit growth in H2 2024. Shares rose by 2.47%.
Despite a revenue decline due to external factors, InterCure's profitability and strategic expansion in Germany with Cookies suggest positive future growth. The market reacted positively with a 2.47% share price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
InterCure plans to launch over 30 new GMP SKUs in collaboration with Organigram and others in H2 2024, indicating potential growth and increased market presence.
InterCure's collaboration with Organigram for new product launches suggests potential growth for both companies. This strategic move could enhance Organigram's market presence.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50